Liver-directed gene therapy
to restore natural euglycemia
Liver-directed gene therapy
to restore natural euglycemia
Liver cells are already capable of insulin production. Our technology uses a patented genetic factor to activate this ability to produce and regulate insulin via the liver, which as the next major organ after the pancreas in the blood pathway from the intestines, it is in the best position to respond rapidly to changing blood glucose levels. This approach is how we are working toward our goal of achieving independence from insulin for Type 1 patients.
In addition, studies with genetically engineered liver cells indicate that these cells are likely to be resistant to autoimmune destruction.